We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

122 hedge funds and large institutions have $359M invested in CytomX Therapeutics in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 56 increasing their positions, 35 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 35

2.89% more ownership

Funds ownership: 84.31% → 87.2% (+2.9%)

3% less funds holding

Funds holding: 126 → 122 (-4)

15% less capital invested

Capital invested by funds: $422M → $359M (-$63.1M)

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

62% less call options, than puts

Call options by funds: $132K | Put options by funds: $351K

Holders
122
Holders Change
-4
Holders Change %
-3.17%
% of All Funds
2.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
56
Reduced
35
Closed
17
Calls
$132K
Puts
$351K
Net Calls
-$219K
Net Calls Change
-$36K

Top Buyers

Rank Fund Capital Flow
1
CS
Candriam SCA
Luxembourg
+$18.1M
2
O
OrbiMed
New York
+$11.8M
3
State Street
State Street
Massachusetts
+$9.79M
4
GPP
Great Point Partners
Connecticut
+$7.79M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$6.36M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$43.1M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$7.85M
3
PA
Perceptive Advisors
New York
-$3.99M
4
Renaissance Technologies
Renaissance Technologies
New York
-$3.32M
5
Two Sigma Investments
Two Sigma Investments
New York
-$3.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
51
ALPS Advisors
Colorado
$542K +$15.6K +2,000 +2%
Jane Street
52
Jane Street
New York
$536K +$524K +67,330 +387%
Two Sigma Investments
53
Two Sigma Investments
New York
$534K -$3.11M -399,600 -83%
PAG
54
Private Advisor Group
New Jersey
$533K -$7.79K -1,000 -1%
HP
55
Harbourvest Partners
Massachusetts
$501K – – –
PP
56
PDT Partners
New York
$479K +$242K +31,132 +70%
ROTUOC
57
Regents of the University of California
California
$475K – – –
AAA
58
Affinity Asset Advisors
New York
$475K +$195K +25,000 +50%
Los Angeles Capital Management
59
Los Angeles Capital Management
California
$454K +$24.8K +3,190 +5%
UBS AM
60
UBS AM
Illinois
$410K +$275K +35,254 +119%
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
$406K +$24.8K +3,190 +5%
SEI Investments
62
SEI Investments
Pennsylvania
$399K -$111K -14,310 -18%
AllianceBernstein
63
AllianceBernstein
Tennessee
$361K +$80.2K +10,300 +22%
EGM
64
Engineers Gate Manager
New York
$348K +$199K +25,535 +87%
Wells Fargo
65
Wells Fargo
California
$335K -$715K -91,777 -63%
QI
66
QS Investors
New York
$322K +$396K +50,800 New
New York State Common Retirement Fund
67
New York State Common Retirement Fund
New York
$313K +$50.5K +6,483 +15%
CS
68
Credit Suisse
Switzerland
$289K +$29K +3,718 +9%
FQ
69
First Quadrant
California
$273K -$340K -43,600 -50%
Deutsche Bank
70
Deutsche Bank
Germany
$257K -$6.56K -843 -2%
SFI
71
Susquehanna Fundamental Investments
Pennsylvania
$250K +$307K +39,463 New
Manulife (Manufacturers Life Insurance)
72
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$249K +$14.5K +1,860 +5%
PPA
73
Parametric Portfolio Associates
Washington
$248K -$161K -20,621 -34%
Ohio Public Employees Retirement System (OPERS)
74
Ohio Public Employees Retirement System (OPERS)
Ohio
$219K +$269K +34,609 New
VEA
75
Virtus ETF Advisers
New York
$196K -$55.5K -7,125 -19%
1 2
3
4 5

CTMX Hedge Fund Activity: Q2 2021 in Review

122 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2021, worth a combined $359M — down 15% from $422M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of CTMX and 14 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 56 added.

The largest buyer was Candriam SCA, adding an estimated $18.1M. The largest seller was BVF Inc, exiting entirely with an estimated $43.1M sold.

  • 122 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2021, down from 126 in Q1 2021.
  • Funds reported $359M of CytomX Therapeutics stock for Q2 2021, down 15% quarter-over-quarter.
  • 14 funds opened new CytomX Therapeutics positions in Q2 2021 and 17 closed out, a net change of -3 holders.
  • The largest CytomX Therapeutics buyer in Q2 2021 was Candriam SCA, an estimated $18.1M added.
  • The largest CytomX Therapeutics seller in Q2 2021 was BVF Inc, an estimated $43.1M sold.

Based on aggregated 13F filings for Q2 2021.